Neurocrine Biosciences (NBIX) Total Liabilities (2010 - 2026)

Neurocrine Biosciences has reported Total Liabilities for 17 years, with the latest figure at $1.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 30.1% year-over-year to $1.5 billion; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 30.1% YoY), and the FY2025 full-year result was $1.4 billion, up 22.09% from the prior year.
• Total Liabilities for Q1 2026 stood at $1.5 billion, up from $1.4 billion in the prior quarter.
• The five-year high for Total Liabilities was $1.5 billion in Q1 2026, with the low at $582.3 million in Q2 2022.
• Historically, Total Liabilities has averaged $953.5 million across 5 years, with a median of $846.1 million in 2023.
• Annual changes were most pronounced in 2022 — Total Liabilities fell 14.01% — and 2024, when it soared 60.86%.
• Neurocrine Biosciences' Total Liabilities stood at $660.9 million in 2022, then surged by 54.24% to $1.0 billion in 2023, then grew by 10.75% to $1.1 billion in 2024, then rose by 22.09% to $1.4 billion in 2025, then gained by 8.73% to $1.5 billion in 2026.
• The last three Total Liabilities figures came in at $1.5 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.